Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
240 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, et al. · JAMA · 2024Clinical Trial, Phase III, Multicenter Study
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Look M, Dunn JP, Kushner RF, et al. · Diabetes Obes Metab · 2025Clinical Trial, Phase III, Multicenter Study
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med · 2025Clinical Trial, Phase III, Comparative Study
- Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · N Engl J Med · 2022Clinical Trial, Phase III, Randomized Controlled Trial
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Packer M, Zile MR, Kramer CM, et al. · N Engl J Med · 2025Clinical Trial, Phase III, Multicenter Study
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism · 2025Network Meta-Analysis, Systematic Review
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Zhao L, Cheng Z, Lu Y, et al. · JAMA · 2024Clinical Trial, Phase III, Multicenter Study
- Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.
Ismaiel A, Scarlata GGM, Boitos I, et al. · Int J Obes (Lond) · 2025Network Meta-Analysis, Systematic Review
- Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
Berg S, Stickle H, Rose SJ, et al. · Obes Rev · 2025Meta-Analysis, Systematic Review
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, et al. · Lancet · 2023Randomized Controlled Trial, Multicenter Study
- Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Merola JF, Mease P, Kivitz A, et al. · Arthritis Rheumatol · 2026Clinical Trial, Phase III, Multicenter Study
- Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
Shukla AP, Dunn JP, Gomez Valderas E, et al. · Diabetes Obes Metab · 2026Clinical Trial, Phase III, Comparative Study
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
Moiz A, Filion KB, Toutounchi H, et al. · Ann Intern Med · 2025Systematic Review
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T, Avgerinos I, Liakos A, et al. · Diabetologia · 2022Meta-Analysis, Systematic Review
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
McGowan B, Ciudin A, Baker JL, et al. · Nat Med · 2025Systematic Review, Network Meta-Analysis
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH, Qazi SU, Sajid F, et al. · Endocr Pract · 2024Meta-Analysis, Systematic Review
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
Galli M, Benenati S, Laudani C, et al. · J Am Coll Cardiol · 2025Systematic Review, Meta-Analysis
- Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
Tan B, Pan XH, Chew HSJ, et al. · Int J Obes (Lond) · 2023Meta-Analysis, Systematic Review
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
Kanu C, Shinde S, Chakladar S, et al. · Sleep Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, Xu J, Mu X, et al. · Front Endocrinol (Lausanne) · 2023Meta-Analysis, Systematic Review
- GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.
Ahmad N, Alruwayyes A, Alarjani A, et al. · Medicine (Baltimore) · 2026Systematic Review, Network Meta-Analysis
- Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Horn DB, Aronne LJ, Wharton S, et al. · Lancet · 2026Multicenter Study, Randomized Controlled Trial
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Sloop KW, Loghin C, et al. · Mol Metab · 2018Clinical Trial, Phase I, Randomized Controlled Trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.